The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | BTKis in WM: ibrutinib versus zanubrutinib and the use of non-covalent BTKis
Marek Trněný, MD, PhD, Charles University Hospital, Prague, Czech Republic, discusses the evolution of BTK inhibitors (BTKis) in the Waldenström’s macroglobulinemia (WM) treatment landscape. He compares the efficacy and tolerability of zanubrutinib and ibrutinib, and considers the potential use of pirtobrutinib after covalent BTKi failure. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Roche, Takeda, Gilead, Abbvie, Caribou, GenMab, BMS, Janssen, Morphosys, Novartis, SOBI, Autolus; Research Support: Roche; Honoraria: Roche, Takeda, Gilead, Abbvie, SOBI, Caribou, Autolus, GenMab, Janssen.
